Applied Molecular extends losses as bowel disease drug trial data disappoints

Applied Molecular Transport.

23/12/2022 15:44

** Shares of drug developer Applied Molecular Transport Inc
 AMTI.O  fall ~58% to a record low of 43 cents
    ** Company late on Thursday reported data from a mid-stage
study of its experimental drug, AMT-101, for treating patients
with moderate-to-severe ulcerative colitis 
    ** Ulcerative colitis is an inflammatory bowel disease that
causes inflammation and ulcers in the digestive tract
    ** Clinical remission rate in patients treated with AMT-101
as a monotherapy was 17.1%, vs 20% with placebo - Applied
Molecular
    ** Company says it plans to seek a partner to advance the
program into late-stage study
    ** Including session's losses, shares of Applied Molecular
down ~96% YTD
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))